Sign In
Buy TRIN
$17.55
+0.140 (+0.80%)
At Close: Jul 31, 2026
Monthly Dividends Begin in January; Q4 Marks the 24th Consecutive Quarter of a Consistent Dividend PHOENIX , Dec. 17, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a lead
Buy Any Of Santa's 14 Ideal Safer Dividend Power Dogs
02:26am, Saturday, 13'th Dec 2025
The December Dividend Power list identifies 35 high-yield stocks, with 14 offering 'safer' dividends backed by free cash flow yields exceeding dividend yields. Top actionable picks include Annaly Capi
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle's disappointing earnings after the bell yesterday. The Federal Reserve's 25-basis-p
Trinity Capital: Why I Put 25% Of My Portfolio Into This BDC
06:48am, Saturday, 06'th Dec 2025
Trinity Capital stands out as an internally managed BDC with strong management-shareholder alignment and a robust track record in growth-stage lending. TRIN consistently covers its $0.51 quarterly div
Trinity Capital: Despite Risks, 14% Yield Worth Considering
09:39am, Friday, 05'th Dec 2025
Trinity Capital stands out in the BDC space for its ~14% dividend yield, niche growth strategy, internal management, growing net investment income and rising book value. However, it faces risks, inclu
Trinity Capital Inc. Provides Equipment Financing to Sortera Technologies to Scale AI-Powered Upcycling Innovation
08:00am, Thursday, 04'th Dec 2025
PHOENIX , Dec. 4, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) ("Trinity Capital"), a leading alternative asset manager, today announced the commitment of equipment financing to Sortera Te
Trinity Capital Inc. Provides Growth Capital to Kinetic to Expand Workplace Injury Management Technology
08:00am, Tuesday, 02'nd Dec 2025
PHOENIX , Dec. 2, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of growth capital to Kinetic, a leading
The Hidden Risk In BDC Market That Nobody Is Talking About
09:15am, Monday, 01'st Dec 2025
BDCs are facing pressures from multiple fronts. Yet, they do not have much ammo left to fight back via portfolio growth. This is not good for shareholder and BDC managers, who earn fees based on asset
Don't Fear The Pivot: 2 BDCs Built For 10%+ Yields In New Rate Regime
09:15am, Wednesday, 26'th Nov 2025
BDC earnings are sensitive to interest rates. As there is no meaningful margin of safety in the BDC system, forthcoming interest rate cuts might trigger a wave of dividend cuts. For prudent passive in
Worried About Rate Cuts? 2 BDCs Best Positioned For The Storm
06:55am, Sunday, 23'rd Nov 2025
Hercules Capital and Trinity Capital are best positioned among BDCs to sustain base dividends amid possible lower interest rates. Both HTGC and TRIN benefit from strong fundamentals, investment-grade
October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs
05:43pm, Wednesday, 19'th Nov 2025
This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LY
Don't Bury BDC Dividends Just Yet
11:21am, Monday, 17'th Nov 2025
The Fed's dovishness has been the key driver for the BDC sell-off. The idea is that lower interest rates should lead to lower dividends (i.e., BDCs cutting their dividend across the board). While it i
Dividend Power Dogs: 12 Ideal Safer November Stars
08:38am, Sunday, 16'th Nov 2025
Of 35 November Dividend Power Dogs, 12 are recommended for "safer" dividends, with free-cash-flow-yields exceeding dividend-yields, and returns from $1,000 invested equaling-or-exceeding share-price,
The BDC Bargain Bell Is Ringing
09:15am, Thursday, 13'th Nov 2025
BDCs have had a rough year so far. Yet, Q3 earnings data points indicate that the tide could be turning. While there are some tangible improvements in BDC business environment, many risks remain open.
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
08:25am, Thursday, 13'th Nov 2025
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostat
